Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Sep 09, 2026
Why Is ServiceTitan (TTAN) Stock Down -17% Today?

Why Is ServiceTitan (TTAN) Stock Down -17% Today?

Key Takeaways

  • ServiceTitan (TTAN) shares plunged roughly 17% in Wednesday's session following the company's fiscal second-quarter earnings report.
  • The decline came despite an earnings beat — the market focused instead on softer forward guidance and a sales-leadership transition.
  • Fiscal Q3 revenue guidance of $285–$287 million came in below the roughly $287.8 million consensus, unsettling investors.
  • A wave of analyst price-target reductions (KeyBanc, Piper Sandler, BMO, Citi, Canaccord, and Wells Fargo) added pressure to the stock.
  • Trading volume ran far above average as investors repriced the stock's near-term growth trajectory.

Opening Summary

ServiceTitan, Inc. (TTAN), a cloud-based software provider serving residential and commercial trade contractors in plumbing, electrical, and HVAC, saw its shares fall sharply on Wednesday, down approximately 17% to around $67.69, compared with a prior close of $81.58. The move marked a decisive sell-off that extended losses booked in after-hours trading following Tuesday's quarterly results. While the company topped Wall Street's earnings and revenue estimates, investors zeroed in on a lighter-than-expected third-quarter outlook and an announced change in its chief revenue officer, overshadowing an otherwise solid quarter.

Earnings Beat Overshadowed by Cautious Guidance

The earnings-driven move reflects a classic "beat and drop" dynamic. ServiceTitan (TTAN) reported fiscal second-quarter revenue of $292.76 million, up roughly 21% year over year and ahead of the roughly $285.9 million consensus, alongside adjusted EPS of $0.40 versus the $0.35 analysts expected. Gross transaction volume also rose, and non-GAAP free cash flow improved. Yet the market reaction was decisively negative because the company's forward view disappointed. Management guided fiscal third-quarter revenue to $285–$287 million, modestly below the consensus near $287.8 million, and full-year revenue to a range of $1.139–$1.144 billion. For a high-multiple, growth-oriented software name, even a slight trim to the growth outlook can trigger outsized selling.

Chief Revenue Officer Transition Adds Execution Uncertainty

Compounding the cautious guidance, ServiceTitan (TTAN) announced a leadership change in its sales organization, naming company veteran Rikus Pretorius as its next chief revenue officer, with current CRO Ross Biestman remaining through the end of the fiscal year. While the transition was framed as orderly, investors tend to view changes at the top of a growth company's revenue engine as an execution risk — particularly when paired with a softer outlook. The combination of near-term guidance shortfalls and a sales-leadership shakeup gave traders little reason to defend the stock.

Analyst Price-Target Cuts Reinforced the Downside

Sell-side reaction amplified the selling pressure. Multiple firms trimmed their price objectives even as they largely maintained buy or overweight ratings, including KeyBanc (to $110 from $120), Piper Sandler (to $110 from $115), BMO Capital Markets (to $90 from $103), Citi (to $76 from $83), Canaccord (to $90 from $105), and Wells Fargo (to $105 from $115). Needham and BTIG reiterated constructive ratings with targets of $100 and $110, respectively. The common thread across the notes was that the quarter's beat was smaller than in prior periods, with more moderate job growth and lead volumes pressuring gross transaction volume, alongside revenue-recognition timing tied to the company's "Max" product. This cluster of downward revisions reinforced the bearish sentiment.

Market Context and Trading Activity

The price action was accompanied by unusually heavy volume, with shares changing hands at multiples of the stock's average daily activity — consistent with institutional repositioning rather than retail-driven noise. The move reflected company-specific catalysts rather than broad market weakness, as the sell-off was concentrated in the name itself following its earnings print. Technically, the stock broke decisively below its 50-day moving average (which had stood in the mid-$80s), while the 200-day moving average near the low-$70s loomed as the next area of focus for traders. The sharp intraday range underscored the elevated volatility surrounding the earnings event.

What Comes Next for ServiceTitan (TTAN)

Looking ahead, investors will monitor how ServiceTitan (TTAN) executes against its revised guidance, whether the "Max" product strategy converts early demand into sustained revenue, and how smoothly the CRO transition unfolds. Key watch items include upcoming quarterly results, gross transaction volume trends, usage-based revenue in the HVAC segment, and any further commentary on AI-driven product adoption. Risks include continued moderation in transaction growth, the company's persistent GAAP losses, and elevated insider selling, which totaled tens of millions of dollars over the past 90 days. While consensus ratings remain broadly constructive, near-term sentiment will likely hinge on evidence that growth stabilizes.

Trending AI Robots

Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots that have demonstrated strength under current market conditions. Tickeron offers hundreds of AI trading bots spanning thousands of tickers, with each bot differing by strategy, timeframe, performance metrics, and the symbols it trades. Only the strongest performers are featured in this section, making it a useful starting point for traders exploring systematic, data-driven approaches. Explore the Trending AI Robots to see which strategies are currently leading the market.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: TTAN

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


Momentum Indicator for TTAN turns positive, indicating new upward trend

TTAN saw its Momentum Indicator move above the 0 level on September 23, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator turned positive. In 20 of the 23 cases, the stock moved higher in the following days. The odds of a move higher are at 87%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where TTAN's RSI Indicator exited the oversold zone, 11 of 13 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.

The Moving Average Convergence Divergence (MACD) for TTAN just turned positive on September 29, 2026. Looking at past instances where TTAN's MACD turned positive, the stock continued to rise in 12 of 14 cases over the following month. The odds of a continued upward trend are 86%.

Following a +6.01% 3-day Advance, the price is estimated to grow further. Considering data from situations where TTAN advanced for three days, in 76 of 105 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

TTAN moved below its 50-day moving average on September 08, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for TTAN crossed bearishly below the 50-day moving average on September 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 3 of 4 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 75%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TTAN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

TTAN broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for TTAN entered a downward trend on September 29, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 41 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.600) is normal, around the industry mean (51.456). P/E Ratio (0.000) is within average values for comparable stocks, (82.636). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.135). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (5.211) is also within normal values, averaging (69.875).

The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating fairly steady price growth. TTAN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TTAN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Salesforce (NYSE:CRM), Shopify Inc (NASDAQ:SHOP), Uber Technologies (NYSE:UBER), ServiceNow Inc. (NYSE:NOW), Datadog (NASDAQ:DDOG), Adobe (NASDAQ:ADBE), Intuit (NASDAQ:INTU), Workday (NASDAQ:WDAY), Atlassian Corp (NASDAQ:TEAM), Autodesk (NASDAQ:ADSK).

Industry description

Packaged software comprises multiple software programs bundled together and sold as a group. For example, Microsoft Office includes multiple applications such as Excel, Word, and PowerPoint. In some cases, buying a bundled product is cheaper than purchasing each item individually[s20] . Microsoft Corporation, Oracle Corp. and Adobe are some major American packaged software makers.

Market Cap

The average market capitalization across the Packaged Software Industry is 9.9B. The market cap for tickers in the group ranges from 39 to 244.09B. SAPGF holds the highest valuation in this group at 244.09B. The lowest valued company is STIXF at 39.

High and low price notable news

The average weekly price growth across all stocks in the Packaged Software Industry was 1%. For the same Industry, the average monthly price growth was -6%, and the average quarterly price growth was 12%. RPGL experienced the highest price growth at 180%, while WCT experienced the biggest fall at -87%.

Volume

The average weekly volume growth across all stocks in the Packaged Software Industry was -45%. For the same stocks of the Industry, the average monthly volume growth was 20% and the average quarterly volume growth was -37%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 53
P/E Growth Rating: 76
Price Growth Rating: 59
SMR Rating: 77
Profit Risk Rating: 94
Seasonality Score: 6 (-100 ... +100)
View a ticker or compare two or three
TTAN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry PackagedSoftware

Industry
N/A
Address
800 N. Brand Boulevard
Phone
+1 855 899-0970
Employees
3414
Web
https://www.servicetitan.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
From what I see, Cheniere Energy Partners (CQP) holds a commanding position through its ownership and operation of the Sabine Pass LNG terminal in Louisiana, the largest LNG production facility in the U.S. with approximately 30 million tonnes per annum (mtpa) capacity across six trains, alongside the connected Creole Trail Pipeline. This setup makes CQP a leader in U.S. LNG exports, which have accounted for about 11% of global supply in recent years. The company's ~80% contracted production through long-term sale and purchase agreements (SPAs) provides revenue stability, with weighted average remaining lives of around 13 years.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
As I review BeOne Medicines AG's position in the oncology space, what stands out is its role as a global leader with a diversified portfolio that includes both commercial-stage therapies and a deep pipeline targeting hematologic and solid tumors. The flagship product, BRUKINSA (zanubrutinib), a Bruton's Tyrosine Kinase (BTK) inhibitor, has secured approvals in over 75 markets, solidifying its dominance in chronic lymphocytic leukemia (CLL) and other blood cancers. This is complemented by TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in more than 50 markets for various indications, which broadens its reach in immunotherapy.
Rio Tinto holds a premier position as one of the world's largest mining companies, anchored by low-cost, Tier 1 assets. Its Pilbara iron ore operations in Australia deliver industry-leading margins, thanks to integrated rail and port infrastructure that gives it a structural cost advantage over higher-cost producers. In copper, the company has significant stakes in Escondida, the world's largest copper mine, and full ownership of Oyu Tolgoi in Mongolia, setting it up well to benefit from tightening supply as demand surges for electrification and renewables.
I've always been impressed by how Visa (V) commands the global payments landscape. As an open-loop network, it connects issuers, acquirers, merchants, and consumers without issuing cards or extending credit itself. The VisaNet platform processes over 65,000 transactions per second across more than 200 countries, supporting a ~52% share of the global credit card market and ~60% of debit. This scale generates powerful network effects, where greater adoption benefits everyone involved and creates formidable barriers to entry.
Following the Kenvue consumer health spin-off, Johnson & Johnson has transformed into a focused healthcare leader, emphasizing Innovative Medicine (pharmaceuticals) and MedTech (devices). In my view, this repositioning sharpens the company's edge in high-margin areas such as oncology, immunology, neuroscience, cardiovascular, surgery, and vision, where its diversified portfolio and R&D efficiency provide clear competitive advantages.
I've long appreciated ASML Holding N.V.'s dominant position in the semiconductor lithography market. The company commands over 90% share in advanced deep ultraviolet (DUV) immersion systems and 100% in EUV lithography—the critical technology for chips below 7nm nodes used in AI, high-performance computing, and memory. This near-monopoly comes from decades of R&D investment, exclusive partnerships like Zeiss for optics, and a vast installed base that generates steady service revenue. From what I see, competitors such as Nikon and Canon remain far behind in EUV, sticking to mature nodes.
I've been watching Micron Technology (MU) closely through its recent volatility, which mirrors the semiconductor sector's heightened sensitivity to AI demand and supply constraints. The stock saw a sharp post-earnings sell-off tied to elevated capital expenditure plans, yet it has rebounded with surging DRAM prices—up 90-95%—and memory suppliers booked out for years. From what I see, broader tech optimism, including key partnerships and persistent supply tightness, is driving upward momentum. This positions MU as a pivotal player in high-bandwidth memory (HBM) for data centers. Trading near recent highs around $368, the shares highlight investor focus on Micron's critical role in the AI infrastructure expansion under these constrained industry conditions.